The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel.
Authors
Bourdoumis, AChrisofos, M
Stasinou, T
Christopoulos, Panagiotis
Mourmouris, P
Kostakopoulos, A
Deliveliotis, C
Affiliation
Department of Urology, Torbay Hospital, South Devon Healthcare NHS Foundation Trust, TorquayIssue Date
2015-05
Metadata
Show full item recordAbstract
To investigate potential fluctuations in prostate cancer antigen 3 (PCA 3) scores in castration-resistant prostate cancer (CRPC) patients treated with docetaxel and investigate the assay as a potential prognostic factor.Citation
The role of PCA 3 as a prognostic factor in patients with castration-resistant prostate cancer (CRPC) treated with Docetaxel. 2015, 35 (5):3075-9 Anticancer ResJournal
Anticancer ResearchPubMed ID
25964598Type
ArticleLanguage
enISSN
1791-7530Collections
Related articles
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
- Authors: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
- Issue date: 2014 Feb
- Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
- Authors: Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K
- Issue date: 2012 Oct
- Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
- Authors: Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A, Triptocare Study Group.
- Issue date: 2014 Oct
- Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
- Authors: Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z
- Issue date: 2016 Jan
- Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
- Authors: Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS
- Issue date: 2010 Jun 1